CTX-343, a selective, potent, peripherally restricted LPA1 receptor (LPAR1) antagonist for IPF and other fibrosing lung diseases

/in , /by

Authors – James S. Swaney, Daniel S. Lorrain, Didier Bagnol, Kym I. Lorrain, Alexander R. Broadhead, Timothy R. Watkins, Lisa Eide, Karin J. Stebbins, Michael M. Poon, Jeffrey R. Roppe, Thomas O. Schrader, Austin C. Chen

Date – October 12, 2026

Presented at ICLAF 2026

LPA1 receptor (LPAR1) localization in IPF tissue and functional profiling of PIPE-791, a highly selective, orally dosed LPAR1 antagonist for potential treatment of pulmonary fibrosis

/in , /by

Authors – James S. Swaney, Daniel S. Lorrain, Didier Bagnol, Kym I. Lorrain, Timothy R. Watkins, Michael M. Poon, Jeffrey R. Roppe, Thomas O. Schrader, Austin C. Chen

Date – October 12, 2026

Presented at ICLAF 2026

Identification and Evaluation of [18F] PIPE-497, the First CNS-Penetrant PET Tracer for the Imaging of Lysophosphatidic Acid Receptor 1 in the Clinic

/in , /by

Austin Chen, Christine Sandiego, Guilia Boscutti, Lisa Wells, Chris Baccei, Thomas Schrader, Jeff Roppe, Lino Valdez, Alex Broadhead, Kymmy Lorrain, Didier Bagnol, Karin Stebbins, Mike Poon, Dan Lorrain

Presented at the 2026 Gordon Research Conference on Medicinal Chemistry

LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro

/in , /by

Michael M. Poon, Alexander R. Broadhead, Christopher S. Baccei, Didier Bagnol, Jeffrey R. Roppe, Thomas O. Schrader, Lino Valdez, Yifeng Xiong, Austin C. Chen, Timothy R. Watkins, Daniel S. Lorrain

Presented at ATS 2026

PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists with Distinct Lung Occupancy Profiles and Vascular Effects

/in , /by

Daniel S. Lorrain, Michael M. Poon, Kym I. Lorrain, Alexander R. Broadhead, Didier Bagnol, Jeffrey R. Roppe, Thomas O. Schrader, Austin C. Chen

Presented at ATS 2026

The muscarinic M1 antagonist PIPE-359 demonstrates remyelination in vivo through visual evoked potential (VEP) and electron microscopy (EM) of mice with experimental autoimmune encephalitis (EAE)

/in , /by

Geraldine C Edu, Karin J Stebbins, Alexander R Broadhead, Michael M Poon, Ariana O Lorenzana, Thomas Schrader, Yifeng Xiong, Jill Baccei, Ari J Green, Jonah R Chan, and Daniel S Lorrain

Presented at Neuroscience 2019

Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis

/in , /by

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana O. Lorenzana, Bryanna E. Paulson, Christopher S. Baccei, Jeffrey R. Roppe, Thomas O. Schrader, Lino J. Valdez, Yifeng Xiong, Austin C. Chen & Daniel S. Lorrain

Scientific Reports

Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis

/in , /by

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana J. Lorenzana, Jeffrey R. Roppe, Jill M. Baccei, Christopher S. Baccei, Austin C. Chen, Ari J. Green, Daniel S. Lorrain, and Jonah R. Chan

PNAS

Lysophosphatidic Acid Receptor Subtype-1 Antagonist PIPE-791 Reduces Neuropathic Pain in Macaques

/in , /by

Aldric Hama, Karin Stebbins, Chris Baccei, Daniel Lorrain, Austin Chen, Takahiro Natsume, Hiroryuki Takamatsu

Presented at IASP 2024 World Congress on Pain

The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis

/in , /by

Michael Poon, Kym Lorrain, Alexander Broadhead, Karin Stebbins, Didier Bagnol, Geraldine Edu, Gregory Joseph, Christopher Baccei, Jeffrey Roppe, Thomas Schrader, Lino Valdez, Yifeng Xiong, Austin Chen, and Daniel Lorrain

Respiratory Research

©2026 Contineum Therapeutics Terms of Use Privacy Policy Linkedin Linkedin